SAN DIEGO, June 15, 2026
Halozyme Therapeutics, Inc. has confirmed that it expects zero to minimal impact on royalty revenue through at least 2035 following its review of the newly released draft rule for the Medicare Drug Price Negotiation Program issued by the U.S. Centers for Medicare & Medicaid Services (CMS). The company stated that its assessment of the proposed regulatory framework, combined with provisions established under the One Big Beautiful Bill Act (OBBBA), supports the continued strength of its royalty-generating business model. Halozyme also emphasized that the proposed rule is not expected to affect its ability to secure new licensing agreements for its widely adopted ENHANZE® drug delivery technology, which has become a cornerstone platform for multiple leading biopharmaceutical companies. The announcement provides reassurance to investors and industry stakeholders amid ongoing discussions regarding the potential impact of Medicare drug pricing reforms on pharmaceutical innovation and royalty-based revenue streams.
Regulatory Analysis Supports Stable Long-Term Royalty Outlook
According to Halozyme, the company’s favorable outlook is supported by specific provisions outlined in the CMS proposal, including continued recognition of orphan drug protections and clarification regarding the role of biosimilar competition in determining Medicare negotiation eligibility. Management indicated that these factors significantly reduce the likelihood of meaningful financial disruption to existing royalty agreements over the coming decade. The company’s analysis suggests that products utilizing ENHANZE technology are expected to remain largely insulated from pricing pressures associated with the negotiation program, preserving a key source of recurring revenue.
Halozyme further noted that the draft rule aligns with its existing assumptions regarding future royalty streams and reinforces confidence in its long-term growth strategy. As Medicare pricing reforms continue to evolve, the company plans to remain actively engaged with policymakers and healthcare stakeholders to ensure that innovation-driven technologies continue to receive appropriate recognition within the healthcare ecosystem.
ENHANZE Platform Continues to Drive Partnership Expansion
Advertisement
A major contributor to Halozyme’s confidence is the ongoing success of its proprietary ENHANZE® drug delivery platform, which enables the subcutaneous administration of biologic therapies that would traditionally require intravenous infusion. The technology utilizes the company’s recombinant human hyaluronidase enzyme, rHuPH20, to facilitate the rapid dispersion and absorption of large-volume injectable medications. To date, ENHANZE has been incorporated into ten commercialized products across more than 100 global markets, reaching over one million patients worldwide.
The platform has been licensed to many of the world’s leading pharmaceutical and biotechnology companies, including major developers of oncology, immunology and rare disease therapies. Halozyme emphasized that improving patient convenience, reducing treatment burden and enabling administration in alternative care settings remain key drivers behind partner adoption. Importantly, management stated that the Medicare proposal is not expected to reduce demand for future ENHANZE licensing agreements, preserving opportunities for continued expansion of its partnership portfolio.
Broad Technology Portfolio Strengthens Future Growth Potential
Beyond ENHANZE, Halozyme continues to expand its technology platform through investments in next-generation drug delivery innovations. The company has broadened its capabilities with Hypercon™ microparticle technology and additional hyperconcentration platforms designed to support the delivery of highly concentrated biologics through subcutaneous administration. These technologies aim to reduce injection volume while improving convenience and enabling treatment in both home and healthcare-provider settings. Halozyme has already secured licensing agreements for Hypercon technology with several major biopharmaceutical companies, further diversifying its revenue base.
Combined with its portfolio of proprietary drug-device combination products and advanced auto-injector technologies, the company remains focused on enhancing treatment accessibility and patient adherence across a wide range of therapeutic areas. As regulatory discussions surrounding Medicare pricing continue, Halozyme’s latest assessment underscores the resilience of its business model and highlights the strategic value of differentiated drug delivery technologies in the evolving healthcare landscape. The company believes its innovation-driven approach positions it well for sustained growth while continuing to improve patient experiences and treatment outcomes worldwide.
Source: Halozyme Therapeutics press release
